Exosomal miR-193b: A Potential Biomarker and Therapeutic Target for Alzheimer's Disease

In a study conducted by Liu et al., miR-193b was found to be present in the hippocampus of mice with Alzheimer's disease (AD). Overexpression of miR-193b was observed to effectively inhibit the expression of amyloid precursor proteins. Further analysis revealed significantly lower levels of exosomal miR-193b in the serum, plasma, and cerebrospinal fluid (CSF) of AD patients compared to healthy controls. A negative correlation was found between exosomal miR-193b levels and Aβ42 in the CSF of dementia patients. This relationship is illustrated in Figure 1, which depicts the alteration trends of exosomal miRNAs as potential biomarkers for neurodegenerative diseases (NDDs). Upregulated exosomal miRNAs are highlighted in red font, while downregulated ones are indicated in green font. Different exosomal miRNAs hold promise as potential therapeutic strategies for NDDs, as indicated by the blue font labeling them as potentially therapeutic for neurodegenerative diseases (192X. Sataer et al.).